JP2024531314A5 - - Google Patents
Info
- Publication number
- JP2024531314A5 JP2024531314A5 JP2024509123A JP2024509123A JP2024531314A5 JP 2024531314 A5 JP2024531314 A5 JP 2024531314A5 JP 2024509123 A JP2024509123 A JP 2024509123A JP 2024509123 A JP2024509123 A JP 2024509123A JP 2024531314 A5 JP2024531314 A5 JP 2024531314A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ofatumumab
- composition according
- treatment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233524P | 2021-08-16 | 2021-08-16 | |
| US63/233,524 | 2021-08-16 | ||
| US202163254684P | 2021-10-12 | 2021-10-12 | |
| US63/254,684 | 2021-10-12 | ||
| EP21206466 | 2021-11-04 | ||
| EP21206466.1 | 2021-11-04 | ||
| PCT/EP2022/071132 WO2023020802A1 (en) | 2021-08-16 | 2022-07-27 | Ofatumumab for treating pediatric ms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531314A JP2024531314A (ja) | 2024-08-29 |
| JP2024531314A5 true JP2024531314A5 (https=) | 2025-08-07 |
Family
ID=82940064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509123A Pending JP2024531314A (ja) | 2021-08-16 | 2022-07-27 | 小児ｍｓを治療するためのオファツムマブ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240343821A1 (https=) |
| EP (1) | EP4387999A1 (https=) |
| JP (1) | JP2024531314A (https=) |
| KR (1) | KR20240046200A (https=) |
| CA (1) | CA3229704A1 (https=) |
| IL (1) | IL310813A (https=) |
| WO (1) | WO2023020802A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3733712T (lt) | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| EP4707302A2 (en) * | 2020-04-09 | 2026-03-11 | Novartis AG | Ofatumumab for treating ms while maintaining serum igg |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
-
2022
- 2022-07-27 US US18/683,858 patent/US20240343821A1/en active Pending
- 2022-07-27 EP EP22755216.3A patent/EP4387999A1/en active Pending
- 2022-07-27 WO PCT/EP2022/071132 patent/WO2023020802A1/en not_active Ceased
- 2022-07-27 JP JP2024509123A patent/JP2024531314A/ja active Pending
- 2022-07-27 IL IL310813A patent/IL310813A/en unknown
- 2022-07-27 CA CA3229704A patent/CA3229704A1/en active Pending
- 2022-07-27 KR KR1020247007246A patent/KR20240046200A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024531314A5 (https=) | ||
| IFNB Multiple Sclerosis Study Group | Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial | |
| EP2785349B2 (en) | Combination treatment of cancer | |
| JP2000514091A (ja) | 心筋症の処置 | |
| JP2020526514A5 (https=) | ||
| JP2015520188A5 (https=) | ||
| JP2020537637A5 (https=) | ||
| CA2653201A1 (en) | Compositions and uses of e3-gp19k for treating diabetes | |
| JP7818412B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| RU2592983C2 (ru) | Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака | |
| US5491150A (en) | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome | |
| CN1835765A (zh) | 治疗病毒感染的方法 | |
| JPS62145029A (ja) | インタ−フエロン組成物 | |
| JP2023510609A (ja) | Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法 | |
| JP3568208B2 (ja) | 弱毒化された非免疫原性ポックスウイルスまたはパラポックスウイルスからの多種有効性パラポックス免疫誘導剤の薬剤としての使用のための新規薬効 | |
| JP2023509520A5 (https=) | ||
| JP2024541257A (ja) | キノリノン誘導体の免疫性血小板減少症を治療するための使用 | |
| JP2759050B2 (ja) | 突発性難聴治療用医薬組成物 | |
| JP2024541257A5 (https=) | ||
| JPH0651639B2 (ja) | 後天性免疫不全に関係した骨髄抑止の治療 | |
| JPH02304100A (ja) | ブタの肺炎または関連細菌病の予防または治療に使用するためのインターフェロン | |
| WO2021225960A2 (en) | Beta thymosin peptides for treating viral infections | |
| HK40123216A (zh) | 一种治疗多发性硬化症的方法 | |
| WO2025208443A1 (en) | Methods of treatment warm autoimmune hemolytic anemia using sovleplenib | |
| JP2025537848A (ja) | 多発性硬化症の治療方法 |